Labcorp Enters into Agreement with OPKO Health to Acquire Select Assets of BioReference Health
Dr. Frost has been CEO and Chairman of OPKO since March 2007. Previously, he served at Teva Pharmaceuticals Industries, Limited (Teva) as Chairman and Vice Chairman, and as Chairman and CEO of IVAX Corporation from 1987 until its acquisition by Teva in January 2006. He has served as Chairman for Key Pharmaceuticals and Ladenburg Thalmann Financial Services, and was a Director of Continucare Corporation and Castle Brands. He was also a Governor and Co-Vice Chairman of the American Stock Exchange.
Dr. Frost is a past Chairman and currently serves as a member of the Board of Trustees of the University of Miami, the Shanghai Institute for Advanced Immunochemical Studies in China, and as a Trustee of the Miami Jewish Home for the Aged and the Mount Sinai Medical Center. He also serves as a member of the Executive Committee of the Phillip and Patricia Frost Museum of Science. At the University of Miami, Dr. and Mrs. Frost have endowed the Phillip and Patricia Frost School of Music, the Phillip and Patricia Frost Institute of Chemistry & Molecular Sciences and the Phillip Frost Department of Dermatology. He is a past member of the Board of Trustees of the Scripps Research Institute, the Board of Regents of The Smithsonian Institution and the Skolkovo Foundation Scientific Advisory Council in Russia.
Dr. Frost is a Director of Cocrystal Pharma, a publicly traded biotechnology company developing new treatments for viral diseases.
Dr. Hsiao has served as Vice Chairman and Chief Technical Officer at OPKO since May 2007 and as a Director since February 2007. Previously, Dr. Hsiao served as Vice Chairman-Technical Affairs of IVAX, and as Chairman, CEO and President of IVAX Animal Health, IVAX's veterinary products subsidiary. She also served on the boards of Sorrento Therapeutics, PROLOR Biotech, SafeStitch Medical and Neovasc.
Since 2008 Dr. Hsiao has served as Chairman of the Board of Non-Invasive Monitoring Systems, a medical device company, and was named interim CEO of the company in 2012. Dr. Hsiao is also a Director of TransEnterix, a medical device company, and Cocrystal Pharma.
Dr. Zerhouni is Chairman and co-founder of ModeX Therapeutics, OPKO’s wholly-owned subsidiary focused on delivering multispecific therapies for cancer and viral diseases, and has served as President and Vice Chairman of OPKO since May 2022. A physician-scientist in Imaging and Biomedical Engineering, he previously served as President of Global R&D and Executive Vice President of Sanofi, as Senior Fellow for global health research at the Bill & Melinda Gates Foundation and as Presidential U.S. envoy for science and technology. He was Director of the U.S. National Institutes of Health, Executive Vice Dean and Dean for Research at the Johns Hopkins School of Medicine, as well as Professor of Radiology and Biomedical Engineering and Chair of the Department of Radiological Sciences.
Dr. Zerhouni was elected to the National Academy of Medicine and to the National Academy of Engineering. He serves on the Board of the Lasker Foundation, the Foundation for the National Institutes of Health and Research!America. He received the 2017 Scripps Executive of the Year Award for the pharmaceutical industry and the French Legion of Honor in 2008. He is a Director of Danaher Corporation, a publicly traded medical, research and industrial products company.
Dr. Abbadessa has been Chief Medical Officer of ModeX. He is an entrepreneurial oncology developer with advanced technical and leadership experience. In his previous post at Sanofi, he rose to become Global Project Head and Vice President, Oncology Early Development, and ushered in numerous oncology therapies at all phases of development including preclinical. He has published over 50 peer-reviewed articles in medical and scientific journals and continues to be active in the oncology community.
In addition, Dr. Abbadessa serves on multiple panels and committees, including those of European Society for Medical Oncology – Targeted Anticancer Therapies. He completed his oncology clinical fellowship in Milan, Italy, and his genetic oncology training at the University of Siena, Italy and the Temple-Fox Chase Cancer Center in Philadelphia.
Mr. Berner has been with OPKO since 2009 and since April 2018 has served as President of OPKO Health Iberoamerica, which encompasses business units in Brazil, Chile, Mexico, Spain and Uruguay. Mr. Berner has extensive experience in the Latin American pharmaceutical industry, previously overseeing operations in Argentina, Mexico and Uruguay as Corporative General Manager of Laboratorios ELEA S.A. Additionally, he worked as both the Latin American Regional Director for the IVAX Corporation and the General Manager of IVAX Argentina and IVAX Uruguay. He also served as Business Development Manager at Laboratorio Chile S.A. and as Finance Manager at ING Bank Chile.
With over 15 years of teaching experience at various universities, Mr. Berner holds a Professorship at the Pontificia Universidad Católica de Chile, instructing MBA students in the subjects of competitive strategy and M&A.
Mr. Berner earned a commercial engineering degree from the Universidad de Santiago de Chile and an MBA from the Business School of Pontificia Universidad Católica Argentina. He subsequently entered post-graduate studies at Babson College in Entrepreneurship, and holds a master’s in clinical and health psychology from TECH Technological University, Spain.
Dr. Bishop has served as CEO of OPKO’s Renal Division since its formation following OPKO's acquisition of Cytochroma in March 2013, where he had served as President and CEO since June 2006. Dr. Bishop co-founded Proventiv Therapeutics and served as President while its lead drug, CTAP101 Capsules, was approved by the FDA as Rayaldee® (calcifediol).
Dr. Bishop held various senior management positions at Bone Care International, a public specialty pharmaceutical company focused on vitamin D hormone therapies, including President, CEO, Director, Executive Vice President of Research and Development and Chief Scientific Officer. Under his direction, Bone Care advanced a portfolio of proprietary vitamin D hormones and analogs to varying stages of development for secondary hyperparathyroidism (SHPT), metabolic bone disease, psoriasis and cancers of the prostate, breast and colon. Bone Care was acquired by Genzyme in July 2005.
Dr. Bishop held various management positions in the Health Care Division of Procter & Gamble. He completed a four-year National Institutes of Health postdoctoral fellowship in vitamin D biochemistry at the University of Wisconsin-Madison and received his Ph.D. degree in nutritional biochemistry from Virginia Tech, after earning an undergraduate degree in chemistry from the University of Virginia. Dr. Bishop has published more than 50 scientific papers and is named on more than 60 U.S. patents.
Mr. Burke has served as CEO of EirGen Pharma, a company specializing in the development and commercial supply of high potency pharmaceutical products including oncology products. He has over 20 years of experience in the pharmaceutical industry and has held a number of senior leadership positions in supply chain, operations and business development. He holds an MSc. in supply chain and operational management from the University of Liverpool.
Established in 2006, EirGen has grown rapidly and now exports products to over 40 countries worldwide including the EU, U.S., Canada and Japan from its state-of-the-art high containment facility. The facility is licensed by the Irish HPRA, U.S. FDA and Japanese PMDA regulatory authorities.
Mr. Logal has served as OPKO's Senior Vice President and Chief Financial Officer since March 2014, and previously as Vice President of Finance, Chief Accounting Officer and Treasurer, Director of Finance and Chief Accounting Officer since our inception in 2007.
Previously, Mr. Logal served in senior management of Nabi Biopharmaceuticals, a publicly traded, biopharmaceutical company engaged in the development and commercialization of proprietary products. There he held various positions of increasing responsibility, last serving as Senior Director of Accounting and Reporting. Mr. Logal served as Chairman of Xenetics Biosciences, a clinical-stage biopharmaceutical company focused on discovery, research and development of next-generation biologic drugs and novel orphan oncology therapeutics from 2017 until 2024. He also previously served as a Director of VBI Vaccines.
Dr. Mascola joined OPKO’s ModeX Therapeutics as Chief Scientific Officer in 2022. He is an accomplished physician-scientist, virologist and immunologist, and was most recently Director of the Vaccine Research Center (VRC), NIAID, NIH where he oversaw research programs on vaccines and antibody therapeutics, as well as the development of investigational products for major diseases such as HIV, Ebola, respiratory syncytial virus, chikungunya and malaria. Under his leadership, the VRC established collaborative partnerships leading to the licensure of therapeutic antibodies and vaccines for Ebola and COVID-19.
Dr. Mascola earned a medical degree from Georgetown University and completed a residency in internal medicine and a fellowship in infectious diseases. He was a research physician at the Walter Reed Army Institute of Research, where he began his studies on HIV immunology and vaccine development. He joined the VRC as a founding investigator and subsequently served as its Director. Dr. Mascola has received numerous awards and recognitions, including the outstanding service medal from the U.S. Department of Health and Human Services. He has been elected to the American Society of Clinical Investigation, the Association of American Physicians and the National Academy of Medicine.
Dr. Nabel is President and CEO of ModeX Therapeutics, and has served as Chief Innovation Officer and a Director of OPKO since May 2022. He previously worked as Chief Scientific Officer and Senior Vice President of Sanofi. A virologist and immunologist, Dr. Nabel served as founding director of NIH’s Vaccine Research Center (VRC) and its leader for 14 years, working on vaccines and broadly neutralizing antibodies against HIV, influenza, SARS, Ebola, Chikungunya and Epstein-Barr virus. He was previously an investigator at the Howard Hughes Medical Institute at the University of Michigan.
In recognition of his expertise at the forefront of virology, immunology, gene therapy and molecular biology, Dr. Nabel was elected to the National Academy of Medicine and is a fellow of the American Association of Physicians, the American Academy of Arts Sciences and the Geoffrey Beene Builders of Science Award from Research America. He served as Board Chair for the non-profit Keystone Symposia and currently serves on the board of Siga Technologies, a publicly traded biotechnology company.
Mr. Rubin has served as Executive Vice President, Administration at OPKO since May 2007 and as a Director since February 2007. Previously, Mr. Rubin was Senior Vice President, General Counsel and Secretary of IVAX.
Mr. Rubin currently serves as a Director of Eloxx Pharmaceuticals, a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates; Non-Invasive Monitoring Systems, a medical device company; Cocrystal Pharma, a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of hepatitis viruses, influenza viruses and noroviruses; ChromaDex, a science-based integrated nutraceutical company devoted to improving the way people age; Neovasc, a company developing and marketing medical specialty vascular devices; and Red Violet, a leading analytics and information solutions provider.
Mr. Rubin previously served as a Director of Castle Brands, Dreams, SafeStitch Medical, Cogent, PROLOR Biotech, BioCardia and VBI Vaccines.
Gene Yau is Head of Business Development where he leads licensing, M&A initiatives and portfolio strategy, to advance the development portfolio and drive enterprise value creation through strategic partnerships and corporate development strategies.
Gene is a seasoned executive who brings over 20 years of experience building and scaling companies through value-defining strategy, partnering, and successful transaction execution. Over his career, he has led transactions totaling over $11 billion in aggregate deal value. Prior to joining OPKO, Gene served as Executive Director and Head of Corporate Development and Strategy at Nimbus Therapeutics, where he led multiple licensing and M&A transactions across its portfolio in immunology, oncology, and metabolic disease. He also held leadership roles at Blueprint Medicines, Astellas, Monsanto, Abbott, and William Blair, building a unique combination of scientific, financial, and strategic expertise across biotechnology and pharmaceuticals.
Gene holds a B.S. in Biochemistry from the University of Illinois Urbana-Champaign, an M.S. in Biotechnology from Northwestern University, and an MBA from the University of Chicago Booth School of Business.
Dr. Frost has been CEO and Chairman of OPKO since March 2007. Previously, he served at Teva Pharmaceuticals Industries, Limited (Teva) as Chairman and Vice Chairman, and as Chairman and CEO of IVAX Corporation from 1987 until its acquisition by Teva in January 2006. He has served as Chairman for Key Pharmaceuticals and Ladenburg Thalmann Financial Services, and was a Director of Continucare Corporation and Castle Brands. He was also a Governor and Co-Vice Chairman of the American Stock Exchange.
Dr. Frost is a past Chairman and currently serves as a member of the Board of Trustees of the University of Miami, the Shanghai Institute for Advanced Immunochemical Studies in China, and as a Trustee of the Miami Jewish Home for the Aged and the Mount Sinai Medical Center. He also serves as a member of the Executive Committee of the Phillip and Patricia Frost Museum of Science. At the University of Miami, Dr. and Mrs. Frost have endowed the Phillip and Patricia Frost School of Music, the Phillip and Patricia Frost Institute of Chemistry & Molecular Sciences and the Phillip Frost Department of Dermatology. He is a past member of the Board of Trustees of the Scripps Research Institute, the Board of Regents of The Smithsonian Institution and the Skolkovo Foundation Scientific Advisory Council in Russia.
Dr. Frost is a Director of Cocrystal Pharma, a publicly traded biotechnology company developing new treatments for viral diseases.
Dr. Hsiao has served as Vice Chairman and Chief Technical Officer at OPKO since May 2007 and as a Director since February 2007. Previously, Dr. Hsiao served as Vice Chairman-Technical Affairs of IVAX, and as Chairman, CEO and President of IVAX Animal Health, IVAX's veterinary products subsidiary. She also served on the boards of Sorrento Therapeutics, PROLOR Biotech, SafeStitch Medical and Neovasc.
Since 2008 Dr. Hsiao has served as Chairman of the Board of Non-Invasive Monitoring Systems, a medical device company, and was named interim CEO of the company in 2012. Dr. Hsiao is also a Director of TransEnterix, a medical device company, and Cocrystal Pharma.
Dr. Zerhouni is Chairman and co-founder of ModeX Therapeutics, OPKO’s wholly-owned subsidiary focused on delivering multispecific therapies for cancer and viral diseases, and has served as President and Vice Chairman of OPKO since May 2022. A physician-scientist in Imaging and Biomedical Engineering, he previously served as President of Global R&D and Executive Vice President of Sanofi, as Senior Fellow for global health research at the Bill & Melinda Gates Foundation and as Presidential U.S. envoy for science and technology. He was Director of the U.S. National Institutes of Health, Executive Vice Dean and Dean for Research at the Johns Hopkins School of Medicine, as well as Professor of Radiology and Biomedical Engineering and Chair of the Department of Radiological Sciences.
Dr. Zerhouni was elected to the National Academy of Medicine and to the National Academy of Engineering. He serves on the Board of the Lasker Foundation, the Foundation for the National Institutes of Health and Research!America. He received the 2017 Scripps Executive of the Year Award for the pharmaceutical industry and the French Legion of Honor in 2008. He is a Director of Danaher Corporation, a publicly traded medical, research and industrial products company.
Dr. Lachman has been a Director of OPKO. He is a healthcare investment manager with more than 35 years of experience in portfolio management, biopharmaceutical investment research and healthcare investment banking. Dr. Lachman founded Maximus Capital in 2001 and currently serves as its general partner. Dr. Lachman previously served as general partner of The Galleon Group and as Managing Director, Investment Research at Goldman Sachs & Co. Dr. Lachman is a Directors Council board member of the Museum of Modern Art, a patron of the Metropolitan Opera and a board member of the Department of Surgery at Mount Sinai Medical Center in New York.
Dr. Yu has been a Director of OPKO since 2009. Previously, she served as Distinguished Research Fellow and Associate Director at the Genomics Research Center, Academia Sinica, in Taiwan. Since 2013, she has been a Distinguished Chair Professor at Chang Gung Memorial Hospital at Linkou, and Chang Gung University in Taiwan.
Dr. Yu has also served as a Professor of Pediatrics for both the National Taiwan University and the University of California San Diego, where she was the Chief of Pediatric Hematology Oncology. Dr. Yu has also served in several government-appointed positions and is a member of numerous scientific committees and associations.
Dr. Medel has been a Director of OPKO. He is the co-founder of MEDNAX, a national health solutions partner comprised of the nation’s leading providers of physician services, where he has served as a Director, President and Chief Executive Officer. Dr. Medel serves as a member of the Board of Trustees of the Dana Farber Cancer Institute and was a member of the Board of Trustees of the University of Miami. Dr. Medel actively participates as a member of several medical and professional organizations and previously served on the Board of Directors of MBF Healthcare Acquisition Corp.
Dr. Nabel is President and CEO of ModeX Therapeutics, and has served as Chief Innovation Officer and a Director of OPKO since May 2022. He previously worked as Chief Scientific Officer and Senior Vice President of Sanofi. A virologist and immunologist, Dr. Nabel served as founding director of NIH’s Vaccine Research Center (VRC) and its leader for 14 years, working on vaccines and broadly neutralizing antibodies against HIV, influenza, SARS, Ebola, Chikungunya and Epstein-Barr virus. He was previously an investigator at the Howard Hughes Medical Institute at the University of Michigan.
In recognition of his expertise at the forefront of virology, immunology, gene therapy and molecular biology, Dr. Nabel was elected to the National Academy of Medicine and is a fellow of the American Association of Physicians, the American Academy of Arts Sciences and the Geoffrey Beene Builders of Science Award from Research America. He served as Board Chair for the non-profit Keystone Symposia and currently serves on the board of Siga Technologies, a publicly traded biotechnology company.
Mr. Paganelli has served as a Director of OPKO since December 2003. Previously, he served as OPKO's interim CEO and Secretary, and Chairman of OPKO's Board of Directors until 2007. Mr. Paganelli also served as President and CEO of Transamerica Life Insurance Company of New York.
Since 1987, Mr. Paganelli has been a partner in RFG Associates, a financial planning organization. Mr. Paganelli is also the Managing Partner of Pharos Systems Partners, an investment company, and served as Chairman of the Board of Pharos Systems International, a software company. He was Vice President and Executive Vice President of PEG Capital Management, an investment advisory organization. Mr. Paganelli was also an officer and director-stockholder of Mike Barnard Chevrolet, an automobile dealership. Mr. Paganelli serves as a Director of Western New York Energy, and previously served on the Board of Trustees of Paul Smith's College and the Board of Managers of Bridge Financial Services.
Mr. Pfenniger has served as a Director of OPKO since January 2008. Mr. Pfenniger previously served as CEO and President for Continucare Corporation, a provider of primary care physician and practice management services, and as Chairman of the Board of Directors of Continucare Corporation. Mr. Pfenniger has also served as CEO and Vice Chairman of Whitman Education Group.
Prior to joining Whitman, he served as Chief Operating Officer of IVAX and as Senior Vice President-Legal Affairs and General Counsel of IVAX. Mr. Pfenniger currently serves as a Director of GP Strategies Corporation, a corporate education and training company, TransEnterix, a medical device company pioneering the use of robotics, IntegraMed America and BioCardia, a clinical-stage regenerative medicine company. He also serves as Vice Chairman of the Board of Trustees and as a member of the Executive Committee of the Phillip and Patricia Frost Museum of Science.
Mr. Rubin has served as Executive Vice President, Administration at OPKO since May 2007 and as a Director since February 2007. Previously, Mr. Rubin was Senior Vice President, General Counsel and Secretary of IVAX.
Mr. Rubin currently serves as a Director of Eloxx Pharmaceuticals, a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates; Non-Invasive Monitoring Systems, a medical device company; Cocrystal Pharma, a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of hepatitis viruses, influenza viruses and noroviruses; ChromaDex, a science-based integrated nutraceutical company devoted to improving the way people age; Neovasc, a company developing and marketing medical specialty vascular devices; and Red Violet, a leading analytics and information solutions provider.
Mr. Rubin previously served as a Director of Castle Brands, Dreams, SafeStitch Medical, Cogent, PROLOR Biotech, BioCardia and VBI Vaccines.
Dr. Uppaluri has served as a Director of OPKO since March 2026. Previously, Dr. Uppaluri served as Senior Vice President and Chief Financial Officer of the Company from May 2007 until his retirement in July 2012, and as a consultant of the Company until February 2014. He served as Vice President, Strategic Planning and Treasurer of IVAX. Dr. Uppaluri served in various positions, including Senior Vice President, Senior Financial Officer, Chief Investment Officer and Controller with several publicly traded banks. He began his career in engineering, marketing and research positions with multinational companies and research institutes in India and the U.S. Dr. Uppaluri currently serves on the board of Baptist Health Homestead Hospital. Dr. Uppaluri previously served on the boards of Non-Invasive Monitoring Systems and at several other publicly traded companies.